Endometrial carcinoma: molecular alterations involved in tumor development and progression. - Wikidata - wikimedia - TriplyDB

Endometrial carcinoma: molecular alterations involved in tumor development and progression.

Endometrial carcinoma: molecular alterations involved in tumor development and progression.

http://www.wikidata.org/entity/Q37994980

about

The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.Molecular mechanisms of tamoxifen-associated endometrial cancer (Review).Signalling pathways in endometrial cancer Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.Modal variety of microsatellite instability in human endometrial carcinomas.Molecular biology of gynecological cancer.Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma.The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcinoma.Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.SOX17 is a tumor suppressor in endometrial cancer Prognostic biomarkers in endometrial and ovarian carcinoma.Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma.The role of pathology in the management of patients with endometrial carcinoma.Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.The enigmatic role of RUNX1 in female-related cancers - current knowledge & future perspectives.Pathology of Endometrial Carcinoma.Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma.Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival.A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium.Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.Advances in endometrial cancer protein biomarkers for use in the clinic.The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

P2860

Q26765913-ABDD2A5B-260D-4B7C-BB19-758C0DF5F80B Q26797456-18140445-CD2F-48B2-941A-402510B23F26 Q28074769-487E3CFB-34F2-4165-A5A2-4E9A44AF785C Q28287769-4EC74C2F-89C4-41EF-91D6-EA6845F8B697 Q28509811-225187B2-6056-42BA-8B85-13B899B96AA3 Q33675285-E497375D-5BB0-491A-AB20-7CD38B1ACEF7 Q33809605-706FF9BB-57C2-474E-93CA-E247198D0972 Q34091442-840996A3-E376-43AC-98E7-ACD15526F424 Q34310001-2C45F1C3-9529-4F75-983C-F4BD925F1EAF Q34458796-F6D88BAE-48BF-40DF-AE2C-E0AEF4DDB663 Q34668715-6BE5BEC0-9113-4E7A-A143-6CED35905007 Q34721660-644AD451-EEF0-454C-BC9B-AB2F5200B56D Q34807396-DBF34F76-056F-472A-9F46-E2DFCC1533A2 Q35125641-42B8D506-98C9-4C51-A813-3FFC1124D38E Q36187533-8A570149-2F17-40A6-9E49-E894CD389D64 Q36223500-7C11C061-A57A-4EFC-B1DE-A610AC4F493D Q36372293-A94AD2BC-F9DD-46F0-8306-D11785DAA84C Q36474899-C8CDAB2E-29BE-4BFF-AC42-515519A71BCD Q36502779-63C984CB-4D42-4A76-AB36-C74286AE0A12 Q36562883-361E1559-D003-45EB-875F-070D7A946A35 Q37295470-788EF805-193E-4A7E-AB2F-7A3722E83F70 Q37457993-BB538136-5A3A-4384-96D1-9C233AE7C764 Q37516309-2FC9992C-0C62-46DB-8C01-C3C016A9F060 Q37660308-A403D8BA-12CA-4D0C-B614-EC431AD1977E Q37689061-FEAF2729-C2D4-4999-96BC-FC25D16ACB93 Q38185940-3AB30353-E1BE-4C1D-9E65-1E344BC2FB6F Q38321607-E0C88A00-93F7-4B4E-A995-549265550701 Q38686652-A40EFE7E-691F-4B2C-9AC0-33E226448F1D Q38725254-05A2DCC9-F1ED-44F7-8A31-149AE82B39F5 Q38743681-ABE9F2D7-AF48-4A50-BAA1-0E8EB8C37908 Q38788207-28BA9B54-A421-4625-AB31-7C06D476A5AC Q38825241-F6E6FB11-0135-46F8-A22B-4F2635D3759B Q39004188-7F8E5C07-CE77-4FD5-88AD-4DD9B953F8C6 Q39165456-AD8D511A-EDE6-494A-BACD-B45065A93697 Q41018493-DE05CCFE-537C-4C9A-91EE-E023C2EE606D Q42509946-CE52E780-2D5E-45DC-8EBC-320E23E8BEA1 Q43720808-443626A3-2CC7-49F7-9CF2-5AF76F1BE872 Q47299584-DB58CFB1-EA32-4348-99CB-B0C9BD022BD4 Q47355920-6252A32E-760A-4848-8C59-74A680EA9402 Q48324030-BC435BA8-B209-41F7-87AA-1497325DDD07

P2860

Endometrial carcinoma: molecular alterations involved in tumor development and progression.

http://www.wikidata.org/entity/Q37994980

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Endometrial carcinoma: molecul ...... r development and progression.

@en

Endometrial carcinoma: molecul ...... r development and progression.

@nl

type

label

Endometrial carcinoma: molecul ...... r development and progression.

@en

Endometrial carcinoma: molecul ...... r development and progression.

@nl

prefLabel

Endometrial carcinoma: molecul ...... r development and progression.

@en

Endometrial carcinoma: molecul ...... r development and progression.

@nl

P1433

Q37994980-CC09F576-A48A-4EDD-A3A3-70BEBCF53C36

P1476

Q37994980-8C62C089-A820-4803-B055-F411853C5504

P2093

Q37994980-16B79057-F310-49A1-B938-9F961F1A825A

Q37994980-2D652C37-195F-424C-8EA3-223FBABC6FCC

Q37994980-33C3E3BF-6C63-4520-9649-05343E701EBC

Q37994980-352BEA8D-8C0E-4FDB-BDDB-2817F0991BAC

Q37994980-5B923BDB-B73F-4261-9272-7E73CE2EE1CD

Q37994980-6EF1E49E-A022-422D-8EBA-C2B0E0010AC0

Q37994980-9F5B1466-0664-437B-AE1B-6193A2083805

Q37994980-A6C1C467-C8D2-4792-A539-EB1FA94B413F

Q37994980-E8BDED50-00B2-427F-B1D5-EEDDFA6C67CC

P2860

Q37994980-01915A87-CB10-4FE5-996F-10C697AB484F

Q37994980-05C9907E-ED50-451B-B384-ADB38FCCC6AC

Q37994980-0989D7D8-D1D7-4844-8B9C-1134111FD189

Q37994980-0CD93CC5-A124-4C94-A0D7-B78E09C8A125

Q37994980-0D51A4A4-828C-44E0-B9AB-EF1C1B701EEC

Q37994980-11D63368-F5E0-482E-B05D-DD724E0B73E8

Q37994980-11F32302-F39D-40EA-9982-45D6588DBE1D

Q37994980-169E3A8C-58A0-4E3A-AC75-1A83A465E104

Q37994980-2500656E-2B9B-43BA-8FBC-83CE83FC305B

Q37994980-2D620392-558A-4072-9B26-2052D12370AA

P2888

Q37994980-6035768C-3B08-4742-9543-1B5CB5A02535

P304

Q37994980-E7FFF3E7-317C-47F6-8CE5-1AEAD0A8A5AE

P31

Q37994980-49F570E9-5F9F-4338-A01E-4086D22EB070

P3181

Q37994980-E9E4C695-B30A-4601-9F6A-B4ABAC20024F

P356

Q37994980-3D33AD7C-132C-4E8C-B9A7-37B8D5B09C2C

P407

Q37994980-E02BE9AE-FEEE-4DDC-81C9-35F5618402EB

P433

Q37994980-D3EDE6E7-473C-4041-B2B1-7101833DFED6

P478

Q37994980-C93393B0-E5B9-4542-96BF-D9A4900F5FEE

P50

Q37994980-DA510C9D-0881-449D-8527-F34CDD7C1C9D

P577

Q37994980-07982D6B-6E68-40C2-859B-693CA59F46D2

P6179

Q37994980-0CD57DA7-F413-4664-8698-55CD7F3B3EB2

P698

Q37994980-1976DF40-F11E-4BE2-8003-C5DBE6002D86

P3181

P356

P1433

P1476

Endometrial carcinoma: molecul ...... r development and progression.

@en

P2093

A Yeramian

http://www.w3.org/2001/XMLSchema#string

E Colas

http://www.w3.org/2001/XMLSchema#string

J Palacios

http://www.w3.org/2001/XMLSchema#string

J Prat

http://www.w3.org/2001/XMLSchema#string

J Reventos

http://www.w3.org/2001/XMLSchema#string

L Catasus

http://www.w3.org/2001/XMLSchema#string

M Abal

http://www.w3.org/2001/XMLSchema#string

X Dolcet

http://www.w3.org/2001/XMLSchema#string

X Matias-Guiu

http://www.w3.org/2001/XMLSchema#string

P2860

hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Essential role for nuclear PTEN in maintaining chromosomal integrity

Subtractive proteomic approach to the endometrial carcinoma invasion front.

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.

Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma.

Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.

Molecular pathology of endometrial hyperplasia and carcinoma.

Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.

P2888

P304

403-413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

551

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/ONC.2012.76

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Gema Moreno-Bueno

P577

2012-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008051020

http://www.w3.org/2001/XMLSchema#string

P698

22430211

http://www.w3.org/2001/XMLSchema#string